合併による増加、受取保険金、研究開発費
- 【期間】
| 年度 | 合併による増加 | 受取保険金 | 研究開発費 |
|---|
| 2011/03 | 1405億 | | - | | - | |
| 2011/06 | - | | - | | - | |
| 2011/09 | - | | - | | - | |
| 2011/12 | - | | - | | - | |
| 2012/03 | - | | - | | - | |
| 2012/06 | - | | - | | - | |
| 2012/09 | - | | - | | - | |
| 2012/12 | - | | - | | - | |
| 2013/03 | - | | - | | 1371億 | |
| 2013/06 | - | | - | | 326億 | -76.3% |
| 2013/09 | - | | - | | 644億 | +97.8% |
| 2013/12 | - | | - | | 892億 | +38.4% |
| 2014/03 | - | | - | | 1153億 | +29.3% |
| 2014/06 | - | | - | | 240億 | -79.2% |
| 2014/09 | - | | - | | 503億 | +109.8% |
| 2014/12 | - | | - | | 702億 | +39.6% |
| 2015/03 | - | | - | | 911億 | +29.8% |
| 2015/06 | - | | - | | 197億 | -78.4% |
| 2015/09 | - | | - | | 467億 | +137% |
| 2015/12 | - | | - | | 701億 | +50.2% |
| 2016/03 | - | | - | | 974億 | +38.8% |
| 2016/06 | - | | - | | 244億 | -74.9% |
| 2016/09 | - | | - | | 499億 | +104.3% |
| 2016/12 | - | | - | | 781億 | +56.5% |
| 2017/03 | - | | - | | 271億 | -65.4% |
| 2017/06 | - | | - | | 608億 | +124.7% |
| 2017/09 | - | | - | | 921億 | +51.6% |
| 2017/12 | - | | - | | 1270億 | +37.8% |
| 2018/03 | - | | - | | 323億 | -74.6% |
| 2018/06 | - | | - | | 634億 | +96.4% |
| 2018/09 | - | | - | | 943億 | +48.8% |
| 2018/12 | - | | - | | 1112億 | +17.8% |
| 2019/12 | - | | - | | 925億 | -16.8% |
| 2020/12 | - | | - | | 937億 | +1.3% |
| 2021/12 | - | | - | | 997億 | +6.4% |
| 2022/03 | - | | -10.1億 | | - | |
| 2022/06 | - | | -10.1億 | ±0% | - | |
| 2022/09 | - | | -14.6億 | 赤拡 | - | |
| 2022/12 | - | | -14.7億 | 赤拡 | 1094億 | +9.7% |
| 2023/03 | - | | -296億 | 赤拡 | - | |
| 2023/06 | - | | -306億 | 赤拡 | - | |
| 2023/09 | - | | -306億 | ±0% | - | |
| 2023/12 | - | | -307億 | 赤拡 | 1242億 | +13.6% |
| 2024/06 | - | | -0.01億 | 赤縮 | - | |
| 2024/09 | - | | -5.03億 | 赤拡 | - | |
